vs
Side-by-side financial comparison of Globalstar, Inc. (GSAT) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
Globalstar, Inc. is the larger business by last-quarter revenue ($72.0M vs $47.7M, roughly 1.5× IRONWOOD PHARMACEUTICALS INC). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -16.1%, a 11.4% gap on every dollar of revenue. On growth, Globalstar, Inc. posted the faster year-over-year revenue change (17.6% vs -47.3%). Over the past eight quarters, Globalstar, Inc.'s revenue compounded faster (12.9% CAGR vs -20.2%).
Globalstar, Inc. is an American telecommunications company that operates a satellite constellation in low Earth orbit (LEO) for satellite phone, low-speed data transmission and Earth observation. The Globalstar second-generation constellation consists of 25 satellites.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
GSAT vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $72.0M | $47.7M |
| Net Profit | $-11.6M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | -0.5% | 14.3% |
| Net Margin | -16.1% | -4.8% |
| Revenue YoY | 17.6% | -47.3% |
| Net Profit YoY | 76.9% | -200.9% |
| EPS (diluted) | $-0.11 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $72.0M | $47.7M | ||
| Q3 25 | $73.8M | $122.1M | ||
| Q2 25 | $67.1M | $85.2M | ||
| Q1 25 | $60.0M | $41.1M | ||
| Q4 24 | $61.2M | $90.5M | ||
| Q3 24 | $72.3M | $91.6M | ||
| Q2 24 | $60.4M | $94.4M | ||
| Q1 24 | $56.5M | $74.9M |
| Q4 25 | $-11.6M | $-2.3M | ||
| Q3 25 | $1.1M | $40.1M | ||
| Q2 25 | $19.2M | $23.6M | ||
| Q1 25 | $-17.3M | $-37.4M | ||
| Q4 24 | $-50.2M | $2.3M | ||
| Q3 24 | $9.9M | $3.6M | ||
| Q2 24 | $-9.7M | $-860.0K | ||
| Q1 24 | $-13.2M | $-4.2M |
| Q4 25 | -0.5% | 14.3% | ||
| Q3 25 | 13.8% | 61.8% | ||
| Q2 25 | 9.2% | 53.2% | ||
| Q1 25 | -14.2% | -70.7% | ||
| Q4 24 | -6.9% | 34.8% | ||
| Q3 24 | 13.0% | 28.0% | ||
| Q2 24 | -2.4% | 26.5% | ||
| Q1 24 | -8.3% | 14.7% |
| Q4 25 | -16.1% | -4.8% | ||
| Q3 25 | 1.5% | 32.8% | ||
| Q2 25 | 28.6% | 27.7% | ||
| Q1 25 | -28.9% | -90.9% | ||
| Q4 24 | -82.1% | 2.5% | ||
| Q3 24 | 13.7% | 4.0% | ||
| Q2 24 | -16.0% | -0.9% | ||
| Q1 24 | -23.4% | -5.6% |
| Q4 25 | $-0.11 | $0.01 | ||
| Q3 25 | $-0.01 | $0.23 | ||
| Q2 25 | $0.13 | $0.14 | ||
| Q1 25 | $-0.16 | $-0.23 | ||
| Q4 24 | $-0.57 | $0.03 | ||
| Q3 24 | $0.00 | $0.02 | ||
| Q2 24 | $-0.01 | $-0.01 | ||
| Q1 24 | $-0.01 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $447.5M | $215.5M |
| Total DebtLower is stronger | $483.8M | — |
| Stockholders' EquityBook value | $355.7M | $-261.8M |
| Total Assets | $2.3B | $396.9M |
| Debt / EquityLower = less leverage | 1.36× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $447.5M | $215.5M | ||
| Q3 25 | $346.3M | $140.4M | ||
| Q2 25 | $308.2M | $92.9M | ||
| Q1 25 | $241.4M | $108.5M | ||
| Q4 24 | $391.2M | $88.6M | ||
| Q3 24 | $51.9M | $88.2M | ||
| Q2 24 | $64.3M | $105.5M | ||
| Q1 24 | $59.3M | $121.5M |
| Q4 25 | $483.8M | — | ||
| Q3 25 | $508.6M | $199.5M | ||
| Q2 25 | $491.5M | $199.3M | ||
| Q1 25 | $502.7M | $199.2M | ||
| Q4 24 | $511.4M | $199.0M | ||
| Q3 24 | $394.4M | $198.8M | ||
| Q2 24 | $393.1M | $198.6M | ||
| Q1 24 | $398.7M | $398.3M |
| Q4 25 | $355.7M | $-261.8M | ||
| Q3 25 | $364.8M | $-264.2M | ||
| Q2 25 | $360.9M | $-308.2M | ||
| Q1 25 | $344.3M | $-334.1M | ||
| Q4 24 | $358.9M | $-301.3M | ||
| Q3 24 | $394.1M | $-311.3M | ||
| Q2 24 | $383.0M | $-321.7M | ||
| Q1 24 | $377.1M | $-330.5M |
| Q4 25 | $2.3B | $396.9M | ||
| Q3 25 | $2.2B | $396.1M | ||
| Q2 25 | $1.9B | $342.9M | ||
| Q1 25 | $1.7B | $327.2M | ||
| Q4 24 | $1.7B | $350.9M | ||
| Q3 24 | $917.6M | $389.5M | ||
| Q2 24 | $926.2M | $395.6M | ||
| Q1 24 | $917.0M | $438.8M |
| Q4 25 | 1.36× | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | 1.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.9M | $74.6M |
| Free Cash FlowOCF − Capex | — | $74.6M |
| FCF MarginFCF / Revenue | — | 156.3% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.9M | $74.6M | ||
| Q3 25 | $236.0M | $47.6M | ||
| Q2 25 | $157.9M | $-15.1M | ||
| Q1 25 | $51.9M | $20.0M | ||
| Q4 24 | $340.7M | $15.2M | ||
| Q3 24 | $32.0M | $9.9M | ||
| Q2 24 | $36.7M | $33.5M | ||
| Q1 24 | $29.8M | $45.0M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.4M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | — | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 60.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 216.53× | 1.19× | ||
| Q2 25 | 8.22× | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | 3.23× | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GSAT
| Services | $67.4M | 94% |
| Products | $4.6M | 6% |
IRWD
Segment breakdown not available.
